All In Biotech

Drug Trial Radar · NCT05857566

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

A Randomized, Open-Label Study of the Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With the Atypical Antipsychotic Drug, Olanzapine

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 16, 2023

Primary completion

Jul 13, 2023

Study completion Sep 13, 2023

Sponsor

Lead sponsor
Response PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.

Conditions

  • Drug-induced Weight Gain

Interventions

  • RDX-002 + OlanzipineDrug

    A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.

  • OlanzapineDrug

    An FDA-approved atypical (second-generation) antipsychotic medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Difference Between the Two Treatment Arms for Postprandial Triglyceride Absolute Area Under the Curve (AUC) on Day 15 vs. Day : 0, 1, 2, 3, 4, 6, and 8 Hours Post DoseTime frame: 7 days
  2. Mean Absolute Difference Between the Two Treatment Arms for Postprandial Triglyceride Absolute AUC on Day 15 vs. Day : 0, 1, 2, 3, 4, 6, and 8 Hours Post DoseTime frame: 7 days
  3. Mean Percent Difference Between the Two Treatment Arms for Postprandial Triglyceride Incremental AUC on Day 15 vs. Day : 0, 1, 2, 3, 4, 6, and 8 Hours Post DoseTime frame: 7 days
  4. Mean Absolute Difference Between the Two Treatment Arms for Postprandial Triglyceride Incremental AUC on Day 15 vs. Day 8: 0, 1, 2, 3, 4, 6, and 8 Hours Post DoseTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.